Arrowhead Pharmaceuticals Inc
Research Arrowhead Pharmaceuticals Inc (ARWR) on Bullrun: market cap USD 11.34B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARWR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.34B
- Financial periodFY2025
- RevenueUSD 829.45M
- Revenue growth23258.2%
- Net income-USD 1.63M
- Free cash flowUSD 156.89M
Valuation Snapshot
latest market cap is USD 11.34B.
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Frequently asked questions
What is Arrowhead Pharmaceuticals Inc's market cap?
Arrowhead Pharmaceuticals Inc's market capitalization is USD 11.34B.
What does Arrowhead Pharmaceuticals Inc do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies;